The current crisis has highlighted the dependence of European and, indeed, North American countries on delocalised production. This is the case for many goods, including APIs and drugs in general.
The opportunity is now there for European CDMOs to win additional business, but effort and adaptation will both be needed. Because I ran a major CDMO for some years, and have since maintained relationship with CDMOs and pharma companies, I feel in a good position to share a few thoughts.
For more information : https://www.specchemonline.com/feature-article-regaining-independence-api-production-chance-european-cdmos
Roger-Marc Nicoud would like to thank the following warmly for sharing their thoughts:
Jean Blehaut, President Manufacturing Solutions BU, Novasep;
Sebastien DAVID, Senior Partner, Advancy;
Oscar Groet, CEO, KD-Pharma;
Olivier Ludemann-Hombourger, Director - Global, Innovation & Technology, PolyPeptide Group;
Pierre Luzeau, CEO, Seqens;
Pablo Magnani, Vice President, Manufacturing & Sales API, Fareva;
Thomas Meier, CEO, Bachem Holding;
Yves Michon, CEO, Corden Pharma Chenôve